乐动体育


Pharma Watch

Leading Pharma Leading Pharma

Challenged Pharma乐动体育 Challenged Pharma

Halozyme Cuts its Lead Oncology Program PEGPH20 & Reduces 55% of Workforce

Halozyme Cuts its Lead Oncology Program PEGPH20 & Reduces 55% of Workforce

乐动体育Biotech venture Halozyme will close its development program for PEGPH20 and instead zero in on delivery technology program. They will lay off 55% of their workforce, reports investment site Seeking Alpha. What Happened? The venture’s oncology operations will be cut...

subscribe

Pin It on Pinterest